Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA Assisted Therapy for Bulimia Nervosa
NCT07542145Phase 1Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- May 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of midomafetamine in bulimia nervosa (BN) (3 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Binge Eating Episode Frequency at 6 months. Started May 2026; status: recruiting.
02
Drugs
midomafetamine
03
Conditions
bulimia nervosa (BN)
Beyond the preview
Go deeper on NCT07542145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07542145.